Cinepazide

History

Cinepazide was discovered by scientists at Laboratoires Delalande (now part of Sanofi) in 1969 in an effort to explore useful substituted cinnamoyl-piperazine compounds. The drug, in the form of a pill taken orally, was launched by Delalande in 1976 under the tradename Vasodistal, for treatment of heart failure, balance disorders, cerebrovascular disease, and vascular complications of diabetes. In 1988 the drug was withdrawn from the market in Spain due to risk of agranulocytosis; other countries where the drug was available added warnings to the label.

In 2002 Sihuan Pharmaceutical brought an injectable form of the drug to market in China; In 2010 it was the highest selling drug in China, with about 1 billion RMB in sales in the 3rd quarter, outselling Plavix in China. This made Sihuan Pharm the largest company in China in the cardio-cerebral vascular drug market in 2010. In 2014 it was the tenth highest-selling drug in China.

References

References

1. "Anjieli, Kelinao, cinepazide maleate - Product Profile - BioCentury".
2. Drugs.com [https://www.drugs.com/international/cinepazide.html Drugs.com International listings for cinepazide] Page accessed Aug 3, 2015
3. 20 Oct 2010 [http://www.bocomgroup.com/mediafiles/documents/p2_4743_en.pdf Sihuan Pharm – China's leading player in cardio-cerebral vascular drug – IPO Report] {{Webarchive. link. (2015-09-23)
4. Sihuan Pharmaceutical [http://www.sihuanpharm.com/index.php?a=show&m=Product&id=60&l=en Kelinao/Anjieli official site] Page accessed Aug 3, 2015
5. (1991). "Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques.
6. (July 1976). "The metabolic fate of the coronary vasodilator 4-(3,4,5-Trimethoxycinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine (cinepazide) in the rat, dog and man". Xenobiotica; the Fate of Foreign Compounds in Biological Systems.
7. Johnson Sun for Guotai Junan International. Sept 28, 2011. [http://pg.jrj.com.cn/acc/Res%5CHK_RES%5CSTOCK%5C2011%5C9%5C28%5C5025ec90-2ed1-473d-bc50-4bc5affe1d83.pdf Company Report: Sihuan Pharmaceuticals]
8. Reactions Weekly 305(1):1. June 1990 [https://link.springer.com/article/10.2165/00128415-199003050-00001 Cinepazide-related agranulocytosis]
9. (1990). "Agranulocytosis induced by cinepazide". European Journal of Clinical Pharmacology.
10. Department of Economic and Social Affairs of the United Nations Secretariat [https://www.un.org/esa/coordination/CL12.pdf Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals] United Nations – New York, 2005
11. Sidney M. Wolfe, M.D. for the Public Citizen's Health Research Group. February 2, 1995. [https://www.citizen.org/documents/1360.pdf Differences in the Number of Drug Safety Withdrawals: United States, United Kingdom, Germany and France 1970-1992]
12. (August 2011). "New drugs for Alzheimer's disease in Japan". Psychiatry and Clinical Neurosciences.
13. Sihuan had acquired the drug from a military hospital in China that had developed the formulation.Su Zhang for Standard Chartered Bank (HK) Limited. June 27, 2014 [http://www.fullertreacymoney.com/system/data/files/PDFs/2014/July/4th/China%20Healthcare.pdf China health care: Pharma sector comes of age]
14. Lefei Sun, Jinsong Du, and Iris Wang for Credit Suisse. October 6, 2011 [https://doc.research-and-analytics.csfb.com/docView?language=ENG&source=ulg&format=PDF&document_id=917625241&serialid=jeGG48ExOvdMDxhWCQXH2AnbdTfWWpDCCuIE71n2tDU%3D China Pharma Sector]